BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DualityBio Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies DualityBio Inc.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05150691-2448@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT05150691)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05150691
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438329-2449@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Sacituzumab drozuntecan: Phase 1/2 readout est. (NCT05438329)
DESCRIPTION:Sacituzumab drozuntecan\, phase 1/2.\nStudy: First-in-human Stu
 dy of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors\nEstimated prima
 ry completion: 13 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05438329
URL:https://assetmemo.bio/drug/sacituzumab-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05914116-2414@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elfetabart drozuntecan: Phase 1/2 readout est. (NCT05914116)
DESCRIPTION:Elfetabart drozuntecan\, phase 1/2.\nStudy: A Phase 1/2a Study 
 of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05914116
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265428-2448@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06265428)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265428
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785741-2450@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:DB-1310: Phase 1/2 readout est. (NCT05785741)
DESCRIPTION:DB-1310\, phase 1/2.\nStudy: A Study of DB-1310 in Advanced/Met
 astatic Solid Tumors\nEstimated primary completion: 30 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/db-1310#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05785741
URL:https://assetmemo.bio/drug/db-1310#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340568-2448@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06340568)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, Endometrial Cancer.\nStudy: 
 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy 
 or Chemotherapy in Patients With Recurring Uterine Cancer\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06340568
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892548-2414@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Elfetabart drozuntecan: Phase 1/2 readout est. (NCT06892548)
DESCRIPTION:Elfetabart drozuntecan\, phase 1/2.\nStudy: A Clinical Study to
  Investigate the Efficacy and Safety of an Investigational Combination The
 rapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer\nEstimat
 ed primary completion: September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06892548
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827236-2448@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Trastuzumab pamirtecan: Phase 1/2 readout est. (NCT06827236)
DESCRIPTION:Trastuzumab pamirtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Clinical Study to Find the Optimal Dose of an Investig
 ational Treatment Called BNT323 When Used in Combination With Another Inve
 stigational Treatment\, BNT327\, and to Test if That Combination Treatment
  is Safe and Beneficial for Patients With Advanced Breast Cancer\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06827236
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038343-2369@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:AVZO-1418: Phase 1/2 readout est. (NCT07038343)
DESCRIPTION:AVZO-1418\, phase 1/2.\nStudy: AVENTINE-1: Study of AVZO-1418 a
 s a Single Agent and in Combination Therapy in Patients With Locally Advan
 ced or Metastatic Solid Tumors (AVZO-1418-1001)\nEstimated primary complet
 ion: June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/avzo-
 1418#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07038343
URL:https://assetmemo.bio/drug/avzo-1418#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953089-2414@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Elfetabart drozuntecan: Phase 2 readout est. (NCT06953089)
DESCRIPTION:Elfetabart drozuntecan\, phase 2.\nStudy: DB-1311 in Combinatio
 n With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/elfetabart-drozuntecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06953089
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365995-2414@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Elfetabart drozuntecan: Phase 3 readout est. (NCT07365995)
DESCRIPTION:Elfetabart drozuntecan\, phase 3\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: A Phase III Trial of BNT324 Versus Docetaxel 
 in Metastatic Castration-resistant Prostate Cancer\nEstimated primary comp
 letion: February 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elfetabart-drozuntecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07365995
URL:https://assetmemo.bio/drug/elfetabart-drozuntecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
